These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 25191732)

  • 1. Clinical importance of the nonalcoholic fatty liver disease: a review.
    Chumak AA; Ovsyannikova LM; Sarkisova EA; Gasanova EV
    Probl Radiac Med Radiobiol; 2013; (18):277-88. PubMed ID: 25191732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New metabolic index in the diagnosis of insulin resistance in patients with nonalcoholic fatty liver disease].
    Roĭtberg GE; Sharkhun OO; Dorosh ZhV
    Eksp Klin Gastroenterol; 2014; (12):13-9. PubMed ID: 26058106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.
    Zhao L; Cang Z; Sun H; Nie X; Wang N; Lu Y
    BMC Endocr Disord; 2017 Feb; 17(1):13. PubMed ID: 28241817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperinsulinemia shifted energy supply from glucose to ketone bodies in early nonalcoholic steatohepatitis from high-fat high-sucrose diet induced Bama minipigs.
    Yang SL; Xia JH; Zhang YY; Fan JG; Wang H; Yuan J; Zhao ZZ; Pan Q; Mu YL; Xin LL; Chen YX; Li K
    Sci Rep; 2015 Sep; 5():13980. PubMed ID: 26358367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effects of Ginkgo biloba leaf polysaccharide on nonalcoholic fatty liver disease and its mechanisms.
    Yan Z; Fan R; Yin S; Zhao X; Liu J; Li L; Zhang W; Ge L
    Int J Biol Macromol; 2015 Sep; 80():573-80. PubMed ID: 26047899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease.
    Chen G; Ni Y; Nagata N; Xu L; Ota T
    Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27563875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [[The Modern View on Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease].].
    Podymova SD
    Eksp Klin Gastroenterol; 2016; (5):74-82. PubMed ID: 28614648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic aspects of adult patients with nonalcoholic fatty liver disease.
    Abenavoli L; Milic N; Di Renzo L; Preveden T; Medić-Stojanoska M; De Lorenzo A
    World J Gastroenterol; 2016 Aug; 22(31):7006-16. PubMed ID: 27610012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NON-ALCOHOLIC FATTY LIVER DISEASE IN ELDERLY.
    Krivosheev AB; Kuimov AD; Popov KV; Kondratova MA; Tuguleva TA; BoGoryanova PA
    Eksp Klin Gastroenterol; 2016; (9):27-31. PubMed ID: 29889391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Dual Role of Nrf2 in Nonalcoholic Fatty Liver Disease: Regulation of Antioxidant Defenses and Hepatic Lipid Metabolism.
    Chambel SS; Santos-Gonçalves A; Duarte TL
    Biomed Res Int; 2015; 2015():597134. PubMed ID: 26120584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood redox status is associated with the likelihood of nonalcoholic fatty liver disease irrespectively of diet's total antioxidant capacity.
    Georgoulis M; Fragopoulou E; Kontogianni MD; Margariti A; Boulamatsi O; Detopoulou P; Tiniakos D; Zafiropoulou R; Papatheodoridis G
    Nutr Res; 2015 Jan; 35(1):41-8. PubMed ID: 25530013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between insulin resistance, metabolic syndrome and nonalcoholic fatty liver disease in non-obese non-diabetic Turkish individuals: A pilot study.
    Erkan G; Sayın I; Polat FB; Çorakçı A; Ataç GK; Değertekin H
    Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():63-8. PubMed ID: 25910371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease: diagnosis, pathogenesis, and management.
    Başaranoğlu M; Örmeci N
    Turk J Gastroenterol; 2014 Apr; 25(2):127-32. PubMed ID: 25003670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic Steatosis as a Marker of Metabolic Dysfunction.
    Fabbrini E; Magkos F
    Nutrients; 2015 Jun; 7(6):4995-5019. PubMed ID: 26102213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial.
    Chen S; Zhao X; Wan J; Ran L; Qin Y; Wang X; Gao Y; Shu F; Zhang Y; Liu P; Zhang Q; Zhu J; Mi M
    Pharmacol Res; 2015 Sep; 99():74-81. PubMed ID: 26032587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of oxidative/nitrosative stress in mice with methionine-choline-deficient diet-induced nonalcoholic fatty liver disease.
    Jorgačević B; Mladenović D; Ninković M; Prokić V; Stanković MN; Aleksić V; Cerović I; Vukićević RJ; Vučević D; Stanković M; Radosavljević T
    Hum Exp Toxicol; 2014 Jul; 33(7):701-9. PubMed ID: 24130212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective.
    Gusdon AM; Song KX; Qu S
    Oxid Med Cell Longev; 2014; 2014():637027. PubMed ID: 25371775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical Importance of Non-alcoholic Fatty Liver Diseases. Topics: II. Complexity in pathogenesis of nonalcoholic fatty liver disease].
    Ikejima K
    Nihon Naika Gakkai Zasshi; 2016 Jan; 105(1):15-24. PubMed ID: 27266039
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones.
    Geisler CE; Renquist BJ
    J Endocrinol; 2017 Jul; 234(1):R1-R21. PubMed ID: 28428362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.